<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02805010</url>
  </required_header>
  <id_info>
    <org_study_id>SIM-126-I</org_study_id>
    <nct_id>NCT02805010</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single Dose of Abatacept 125mg Administered Subcutaneously in Chinese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu Simcere Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the single dose PK, safety, tolerability and
      immunogenicity of abatacept 125mg administered SC in Chinese healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Day1 to Day71</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>Day1 to Day71</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life period (T1/2)</measure>
    <time_frame>Day1 to Day71</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to peak (Tmax)</measure>
    <time_frame>Day1 to Day71</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event (AE)</measure>
    <time_frame>Signed Informed consent form (ICF) to Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-abatacept antibodies</measure>
    <time_frame>Day1 to Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti cytotoxic T lymphocyte-associated antigen-4(CTLA-4) antibodies</measure>
    <time_frame>Day1 to Day 71</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Rheumatoid Arthritis (RA)</condition>
  <arm_group>
    <arm_group_label>Subcutaneous(SC) Abatacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>On Day 1, subjects will receive a single SC dose of abatacept 125mg</description>
    <arm_group_label>Subcutaneous(SC) Abatacept</arm_group_label>
    <other_name>Orencia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>On Day 1, subjects will receive a single SC dose of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects are willing to participate in this study and signed informed consent;

          -  Healthy subjects, as determined by no clinically significant deviation from normal in
             medical history, physical examination, Electrocardiograph（ECG）, and clinical
             laboratory determinations;

          -  Body weight for male must be≥50 kg, for female be≥45 kg, and all subjects must be
             ≤100kg;

          -  Body mass index (BMI) is 19-26 kg/m2 (boundary value included), [BMI = body weight
             (kg) / height (m)2];

          -  Men and women, 18-45 years old (boundary value included);

          -  Women of child bearing potential (WOCBP) must be using the adequate method of
             contraception to avoid pregnancy throughout the study, for 4 weeks before and for up
             to 10 weeks after administration of abatacept, male subjects of childbearing potential
             must be using an adequate method of contraception throughout the study and for up to
             10 weeks after administration of investigational product in such a manner that risk of
             pregnancy is minimized;

               -  WOCBP include any female who has experienced menarche and who has not undergone
                  successful surgical sterilization (hysterectomy, bilateral tubal ligation or
                  bilateral oophorectomy) or is not postmenopausal. Post-menopausal is defined as:
                  Amenorrhea ≥ 12 consecutive months without another cause, or for women with
                  irregular menstrual periods and on hormone replacement therapy (HRT), a
                  documented serum follicle stimulating hormone (FSH) level &gt; 35 mIU/mL;

               -  Women who are using oral, implanted or injectable contraceptive hormones or
                  mechanical products such as an intrauterine device or barrier methods (diaphragm,
                  condoms, spermicides) to prevent pregnancy or practicing abstinence or where
                  partner is sterile (e.g., vasectomy), should be considered to be of child bearing
                  potential;

          -  WOCBP must have a negative serum pregnancy test within 24 hours prior to study
             medication administration.

        Exclusion Criteria:

          -  WOCBP and males subjects of childbearing potential who are unwilling or unable to use
             an acceptable method to avoid pregnancy for up to 10 weeks after administration of the
             study medication;

          -  Women who are pregnant or breast-feeding;

          -  History or concurrent diseases of central nervous system, cardiovascular system,
             renal, hepatic, digestive tract, respiratory system, metabolism and musculoskeletal
             system. (including but not limited to arrhythmia, bradycardia, hypotension, coronary
             heart disease, bronchial asthma, diabetes, hyperthyroidism, Parkinson's disease,
             epilepsy, shaking palsy, cancer, etc.). Or any other diseases or physiological
             abnormalities, which might affect study results;

          -  Any major surgery within 4 weeks of enrollment;

          -  Splenectomized subjects;

          -  Exposed to any investigational medication within 3 months of enrollment, or plan to
             receive other investigational medication during the study;

          -  Donation of blood or plasma within 3 months of enrollment, or plan to donate blood or
             plasma during the study or within one month after the end of the study;

          -  Blood transfusion within 4 weeks prior to enrollment;

          -  Subjects who is a current smoker (defined as individuals who smoked for more than 6
             months, and smoked for ≥ 5 cigarettes per day before screening), ≥ 3 cups of coffee or
             other coffee drinks or ≥ 5 cups of tea per day;

          -  Subjects who have a history of drug or alcohol abuse;

          -  Subjects with tuberculosis (TB) risk, specially:

               -  Having clinical, imaging or lab test evidences of current active or latent
                  pulmonary tuberculosis;

               -  Having active pulmonary tuberculosis during the past 3 years, even if had been
                  treated;

               -  Having history of active pulmonary tuberculosis more than 3 years ago, unless the
                  appropriate duration and types of anti-tuberculosis drug is well documented.

          -  Subjects with herpes zoster that resolved less than 2 months prior to enrollment;

          -  Subjects who had any acute or chronic bacterial infection in the previous 3 months
             prior to enrollment;

          -  Subjects who have acute and latent bacterial and viral infection (as assessed by the
             investigator) at the time of enrollment, including subjects with evidence of Human
             Immunodeficiency Virus (HIV) infection;

          -  Subjects who have mental or physical disability;

          -  Subjects who have any surgical and medical conditions, which might be harmful if
             subjects participate in the study, or which might change the absorption, distribution,
             metabolism and excretion of investigational medication;

          -  Heart beat rate &lt;50 beats /min or &gt;100 beats /min (heart rates should be measured
             after a brief period of rest, at least 5 minutes.), systolic blood pressure &gt;140 mmHg
             or diastolic blood pressure &gt;90 mmHg, body temperature (forehead)&gt;37.6℃;

          -  Hgb &lt; LLN (lower limit of normal), the absolute neutrophil count (ANC) &lt;1.5×10^9/L,
             platelets &lt;100×10^9/L; bilirubin &gt; ULN (upper limit of normal), serum creatinine &gt; ULN
             ; glutamic oxaloacetic transaminase (AST) &gt; ULN, glutamic pyruvic transaminase (ALT) &gt;
             ULN;

          -  Subject who have active infection, or positive for hepatitis-B surface antigen
             (HBs-Ag), hepatitis-C antibody (HCV-Ab), or HIV-Ab;

          -  Positive urinalysis for protein, or other abnormal urinalysis tests which were judged
             to have clinical significance by investigators;

          -  History of drug allergy, postural hypotension, or idiopathic allergy;

          -  Prior exposure to abatacept (CTLA4-Ig), belatacept (LEA29Y) or any leukocyte depleting
             agent;

          -  Use of any prescription drugs within 4 weeks (or 5 half-lives, whichever is longer)
             prior to enrollment, Use of any OTC medications and herbal preparations within 1 week
             prior to enrollment, unless the medical monitoring shows that the drug has been
             cleared;

          -  Vaccination with any live vaccine within 4 weeks prior to study medication
             administration on Day 1;

          -  Administration of oral polio vaccine to subject or house hold contacts during the
             course of study;

          -  Prisoners or subjects who are involuntarily incarcerated;

          -  Subjects who are compulsorily detained for treatment either a psychiatric or physical
             (e.g., infectious disease) illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <last_update_submitted>December 3, 2016</last_update_submitted>
  <last_update_submitted_qc>December 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

